Novo Nordisk exits R&D in inflammatory disorders

exit-way-out

On September 2, 2014, Novo Nordisk officially announced its decision to discontinue all its R&D activities within inflammatory disorders.

The company said that it will increase its focus and efforts more within diabetes prevention and treatment, obesity and diabetes complications.

1 Comment Comment 1 - 1 of 1
comment

Gopal Panday 3 February 2015 at 10:23 PM

AVEQEW

Reply

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X